Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oleanolic acid versus silymarin for nonalcoholic fatty liver disease
ChiCTR1900021568Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of oleanolic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Liver fat content by MRI-proton density fat fraction. Started Jan 2019; status: recruiting.
02
Drugs
oleanolic acid
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR1900021568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021568.